News & Updates

IM noninferior to IV sotrovimab for COVID-19
IM noninferior to IV sotrovimab for COVID-19
17 Feb 2022 byAudrey Abella

In high-risk nonhospitalized patients with mild-to-moderate COVID-19, intramuscular administration of the monoclonal antibody sotrovimab was noninferior to IV infusion of the drug, according to findings from the phase III COMET-TAIL trial presented at CROI 2022.

IM noninferior to IV sotrovimab for COVID-19
17 Feb 2022